Nov 2, 2026
Maureen McBeth, Senior Manager of Clinical Research and Education at ImpediMed, discusses how sarcopenia, age-related muscle loss, significantly impacts the ability of cancer patients to tolerate treatment, yet has historically not been considered very relevant. ImpediMed has developed an FDA-cleared digital health...
Nov 2, 2026
Maureen McBeth, Senior Manager of Clinical Research and Education at ImpediMed, discusses how sarcopenia, age-related muscle loss, significantly impacts the ability of cancer patients to tolerate treatment, yet has historically not been considered very relevant. ImpediMed has developed an FDA-cleared digital health...
Oct 28, 2026
Dr. Aneel Nimba, Medical Director at Faron Pharmaceuticals, discusses the company's innovative approach to treating higher risk myelodysplastic syndromes, a group of rare blood cancers, with its lead drug candidate that targets the CLEVER-1 receptor which controls the tumor microenvironment. This first-in-class...
Oct 28, 2026
Dr. Aneel Nimba, Medical Director at Faron Pharmaceuticals, discusses the company's innovative approach to treating higher risk myelodysplastic syndromes, a group of rare blood cancers, with its lead drug candidate that targets the CLEVER-1 receptor which controls the tumor microenvironment. This first-in-class...
Oct 7, 2026
Dr. John Friend, CEO of Kazia Therapeutics, is investigating how to change the underlying biology that lets cancers resist treatment and evade the immune system. A central challenge in oncology is that cancer cells adapt and suppress immune recognition. Reprogramming the biology includes altering immune evasion...